\
&
Contact us
\
&
Contact us
Published on | 4 months ago
Programmes Agro-Food, EnvironmentCall HORIZON-CL6-2024-BIODIV-02_stage2 has closed on 17/09/2024.
21 proposals have been submitted.
The breakdown per topic is:
HORIZON-CL6-2024-BIODIV-02-1-two-stage: 6 proposals
HORIZON-CL6-2024-BIODIV-02-2-two-stage: 8 proposals
HORIZON-CL6-2024-BIODIV-02-3-two-stage: 7 proposals
Evaluation results are expected to be communicated in January 2025
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI, data & cloud Deployment: Best use of technologies
The European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. The AI Act, which aims to promote innovation while... read more
Digital, Industry & Space Digital Europe Cybersecurity Defence
We would like to inform you that the Commission has adopted and published the European Defence Fund Work Programme 2025. The news announcement (with links to the documents and a factsheet) is available on DEFIS website: https://defence-industry-space.ec.europa.eu/european-defence-fund-over-eu1-billion-drive-next-generation-defence-technologies-and... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
